🇺🇸 FDA
Patent

US 12383582

Methods of treating chronic wounds with amniotic fluid having elevated levels of tissue inhibitors of matrix metalloproteinases

granted A61KA61K35/50A61K45/06

Quick answer

US patent 12383582 (Methods of treating chronic wounds with amniotic fluid having elevated levels of tissue inhibitors of matrix metalloproteinases) held by Prime Merger Sub, LLC expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Prime Merger Sub, LLC
Grant date
Tue Aug 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K35/50, A61K45/06